These findings elucidate the crucial role of NSD2‐mediated H3K36me2 in intestinal barrier impairment, suggesting that targeting intestinal NSD2 can represent a novel therapeutic approach for NASH. This evidence concerns the gene NSD2 and metabolic dysfunction-associated steatohepatitis.